에피루비신

동물 종별 용량

용량은 면허 수의 전문가를 위한 임상 참고 자료입니다. 항상 최신 라벨과 개별 환자에 대해 확인하십시오.

투여 경로

금기

• No specific absolute contraindications listed, but use with extreme caution in patients with pre-existing cardiac disease or the ABCB1 (MDR1) mutation.

이상반응

• Acute anaphylaxis
• Dose-dependent cumulative cardiotoxicity (cardiomyopathy, congestive heart failure)
• Tachycardia and arrhythmias (during administration)
• Anorexia
• Vomiting
• Pancreatitis
• Severe leucopenia
• Thrombocytopenia
• Haemorrhagic gastroenteritis
• Nephrotoxicity
• Severe tissue necrosis (if extravasated)

약물 상호작용

• Heparin · Incompatible; a precipitate will form if mixed. · major
• Cyclophosphamide · Increased risk of myelosuppression when used in combination. · major
• Cimetidine · Increases the area under the dose curve (AUC) of epirubicin by 50%; should not be used concurrently. · major

모니터링

• Complete Blood Count (CBC) and platelet count prior to every dose
• Physical examination and auscultation
• Electrocardiogram (ECG)
• Echocardiogram (especially in breeds predisposed to cardiac disease)
• Renal parameters
• Gastrointestinal signs

과용량

Overdosage increases the risk of severe myelosuppression, severe gastrointestinal toxicity (haemorrhagic gastroenteritis), and acute cardiotoxicity. Treatment is supportive and symptomatic, including aggressive fluid therapy, broad-spectrum antibiotics (if neutropenic), and antiemetics.